In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:

• Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
• Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
• When to consider first-line treatment with immune checkpoint inhibitor monotherapy
• Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy
• Monitoring for and managing immune-related adverse events during the COVID-19 pandemic

 

Presenters:

Petros Grivas, MD, PhD
Associate Professor
Clinical Director, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, Washington, USA

Jonathan E. Rosenberg MD
Attending Physician
Chief, Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York, USA

Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
http://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.